TRPC6 inhibitor (BI 764198) to reduce risk and severity of ARDS due to COVID-19: a phase II randomised controlled trial

BACKGROUND: Despite the availability of COVID-19 vaccinations, there remains a need to investigate treatments to reduce the risk or severity of potentially fatal complications of COVID-19, such as acute respiratory distress syndrome (ARDS). This study evaluated the efficacy and safety of the transie...

Descripción completa

Detalles Bibliográficos
Autores principales: Ware, Lorraine B, Soleymanlou, Nima, McAuley, Danny Francis, Estrada, Vicente, Diaz, George A, Lacamera, Peter, Kaste, Renee, Choi, Wansuk, Gupta, Abhya, Welte, Tobias
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Respiratory Infection
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10359525/
https://www.ncbi.nlm.nih.gov/pubmed/37024277
http://dx.doi.org/10.1136/thorax-2022-219668

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10359525/
https://www.ncbi.nlm.nih.gov/pubmed/37024277
http://dx.doi.org/10.1136/thorax-2022-219668

Ejemplares similares